Search in:

Expert Opinion on Therapeutic Patents Volume 26, 2016 - Issue 10

Submit an article Journal homepage

114

Views

CrossRef citations to date

Altmetric

Patent Evaluation

Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1

Matthieu CollinIntellectual Property Department, INSERM-Transfert, Paris, FranceView further author information

Frédéric JaisserINSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, Paris, France;INSERM, Clinical Investigation Centre 1430, APHP, Henri Mondor Hospital, Pole VERDI, Paris East University, Creteil, FranceCorrespondence[email protected]
View further author information

Pages 1111-1114 | Received 08 Mar 2016, Accepted 18 Aug 2016, Published online: 14 Sep 2016

Cite this article
https://doi.org/10.1080/13543776.2016.1227320
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev. 2016 Jan;68(1):49–75.
PubMed Web of Science ®Google Scholar
Farman N. Molecular and cellular determinants of mineralocorticoid selectivity. Curr Opin Nephrol Hypertens. 1999 Jan;8(1):45–51.
PubMed Web of Science ®Google Scholar
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–717.
PubMed Web of Science ®Google Scholar
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309–1321.
PubMed Web of Science ®Google Scholar
Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 Jan 6;364(1):11–21.
PubMed Web of Science ®Google Scholar
Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417–424.
PubMed Web of Science ®Google Scholar
Collin M, Niemann F, Jaisser F. Mineralocorticoid receptor modulators: a patent review (2007-2012). Expert Opin Ther Pat. 2014 Feb;24(2):177–183.
PubMed Web of Science ®Google Scholar
Yang C, Balsells J, Chu HD, et al. Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists. ACS Med Chem Lett. 2015 Apr 9;6(4):461–465.
PubMed Web of Science ®Google Scholar
Yang C, Shen HC, Wu Z, et al. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists. Bioorg Med Chem Lett. 2013 Aug 1;23(15):4388–4392.
PubMed Web of Science ®Google Scholar
Merck Sharp & Dohme. Mineralocorticoid receptor antagonists. US8933113. 2015.
Google Scholar
Merck Sharp & Dohme. Mineralocorticoid receptor antagonists. EP2665707. 2013.
Google Scholar
Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem. 2010 Aug 26;53(16):5979–6002.
PubMed Web of Science ®Google Scholar
Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012 Jun;14(6):668–675.
PubMed Web of Science ®Google Scholar
Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug;34(31):2453–2463.
Web of Science ®Google Scholar
Pitt B, Anker SD, Böhm M, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015 Feb;17(2):224–232.
PubMed Web of Science ®Google Scholar
Ruilope LM, Agarwal R, Chan JC, et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40(6):572–581.
PubMed Web of Science ®Google Scholar
Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015 Sep 1;314(9):884–894.
PubMed Web of Science ®Google Scholar
Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014 Jul;64(1):69–78.
PubMed Web of Science ®Google Scholar
Merck Sharp & Dohme. Mineralocorticoid receptor antagonists. WO2013055606. 2013.
Google Scholar
Merck Sharp & Dohme. Mineralocorticoid receptor antagonists. WO2013055607. 2013.
Google Scholar
Merck Sharp & Dohme. Mineralocorticoid receptor antagonists. WO2013055608. 2013.
Google Scholar
Merck Sharp & Dohme. Mineralocorticoid receptor antagonists. WO2014014794. 2014.
Google Scholar
Merck Sharp & Dohme. Mineralocorticoid receptor antagonists. WO2012139495. 2012.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date